Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

358 ARTÍCULOS , VIENDO DEL 241 AL 255

[Mechanisms of Alzheimer's disease : Neuronal hyperactivity and hypoactivity as new therapeutic targets]

Busche MA, Staufenbiel M, Willem M, Haass C, Förstl H.

Nervenarzt. 2016 Nov;87(11):1163-1174. doi: 10.1007/s00115-015-0041-5.

Emerging amyloid disease-modifying drugs for Alzheimer's disease

Galimberti D, Scarpini E.

Expert Opin Emerg Drugs. 2016;21(1):5-7. doi: 10.1517/14728214.2016.1146678. Epub 2016 Feb 15.

Nicotinic Acetylcholine Receptors in the Pathophysiology of Al zheimer's Disease: The Role of Protein-Protein Interactions in Current and Future Treatment

Thomsen MS, Andreasen JT, Arvaniti M, Kohlmeier KA.

Curr Pharm Des. 2016;22(14):2015-34. doi: 10.2174/1381612822666160127112357.

Pharmacotherpy and Alzheimer's Disease: The M-Drugs (Melatonin, Minocycline, Modafinil, and Memantine) Approach

Daulatzai MA.

Curr Pharm Des. 2016;22(16):2411-30. doi: 10.2174/1381612822666160203142111.

Predictors of cognitive decline and treatment response in a clinical trial on suspected prodromal Alzheimer's disease

Teipel SJ, Cavedo E, Grothe MJ, Lista S, Galluzzi S, Colliot O, Chupin M, Bakardjian H, Dormont D, Dubois B, Hampel H; Hippocampus Study Group.

Neuropharmacology. 2016 Sep;108:128-35. doi: 10.1016/j.neuropharm.2016.02.005. Epub 2016 Feb 10.

Systematic Review of Model-Based Economic Evaluations of Treatments for Alzheimer's Disease

Hernandez L, Ozen A, DosSantos R, Getsios D.

Pharmacoeconomics. 2016 Jul;34(7):681-707. doi: 10.1007/s40273-016-0392-1.

The Effects of Cognitive Training for Elderly: Results from My Mind Project

Giuli C, Papa R, Lattanzio F, Postacchini D.

Rejuvenation Res. 2016 Dec;19(6):485-494. doi: 10.1089/rej.2015.1791. Epub 2016 Apr 8.

Music and Memory in Alzheimer's Disease and The Potential Underlying Mechanisms

Peck KJ, Girard TA, Russo FA, Fiocco AJ.

J Alzheimers Dis. 2016;51(4):949-59. doi: 10.3233/JAD-150998.

Ethical challenges in preclinical Alzheimer's disease observational studies and trials: Results of the Barcelona summit

Molinuevo JL, Cami J, Carné X, Carrillo MC, Georges J, Isaac MB, Khachaturian Z, Kim SY, Morris JC, Pasquier F, Ritchie C, Sperling R, Karlawish J.

Alzheimers Dement. 2016 May;12(5):614-22. doi: 10.1016/j.jalz.2016.01.009. Epub 2016 Mar 15.

Alzheimer's Disease and Autistic Spectrum Disorder: Is there any Association?

Khan SA, Khan SA, Narendra AR, Mushtaq G, Zahran SA, Khan S, Kamal MA.

CNS Neurol Disord Drug Targets. 2016;15(4):390-402. doi: 10.2174/1871527315666160321104303.

Semantic Feature Training for the Treatment of Anomia in Alzheimer Disease: A Preliminary Investigation

Flanagan KJ, Copland DA, van Hees S, Byrne GJ, Angwin AJ.

Cogn Behav Neurol. 2016 Mar;29(1):32-43. doi: 10.1097/WNN.0000000000000088.

Effects of Citalopram on Neuropsychiatric Symptoms in Alzheimer's Dementia: Evidence From the CitAD Study

Leonpacher AK, Peters ME, Drye LT, Makino KM, Newell JA, Devanand DP, Frangakis C, Munro CA, Mintzer JE, Pollock BG, Rosenberg PB, Schneider LS, Shade DM, Weintraub D, Yesavage J, Lyketsos CG, Porsteinsson AP; CitAD Research Group.

Am J Psychiatry. 2016 May 1;173(5):473-80. doi: 10.1176/appi.ajp.2016.15020248. Epub 2016 Apr 1.

Adrenergic Drugs Blockers or Enhancers for Cognitive Decline ? What to Choose for Alzheimer's Disease Patients?

Femminella GD, Leosco D, Ferrara N, Rengo G.

CNS Neurol Disord Drug Targets. 2016;15(6):665-71. doi: 10.2174/1871527315666160518123201.

Non-Demented Individuals with Alzheimer's Disease Neuropathology: Resistance to Cognitive Decline May Reveal New Treatment Strategies

Zolochevska O, Taglialatela G.

Curr Pharm Des. 2016;22(26):4063-8. doi: 10.2174/1381612822666160518142110.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias